Page 148 - Demo

Chapter 4146References1. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. Nov 19 2015;1:15071. doi:10.1038/nrdp.2015.712. Blagojevic C, Heung T, Theriault M, et al. Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a cross-sectional analysis from population-based newborn screening. CMAJ Open. Jul-Sep 2021;9(3):E802-e809. doi:10.9778/cmajo.202002943. Bassett AS, Chow EW, Husted J, et al. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A. Nov 1 2005;138(4):307-13. doi:10.1002/ajmg.a.309844. Campbell IM, Sheppard SE, Crowley TB, et al. What is new with 22q? An update from the 22q and You Center at the Children’s Hospital of Philadelphia. Am J Med Genet A. Oct 2018;176(10):2058-2069. doi:10.1002/ajmg.a.406375. Schneider M, Debbané M, Bassett AS, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry. Jun 2014;171(6):627-39. doi:10.1176/appi.ajp.2013.130708646. Boot E, Bassett AS, Marras C. 22q11.2 Deletion Syndrome-Associated Parkinson’s Disease. Mov Disord Clin Pract. Jan 2019;6(1):11-16. doi:10.1002/mdc3.126877. Verheij E, Derks LSM, Stegeman I, Thomeer H. Prevalence of hearing loss and clinical otologic manifestations in patients with 22q11.2 deletion syndrome: A literature review. Clin Otolaryngol. Dec 2017;42(6):1319-1328. doi:10.1111/coa.128748. Persson C, Friman V, Óskarsdóttir S, Jönsson R. Speech and hearing in adults with 22q11.2 deletion syndrome. Am J Med Genet A. Dec 2012;158a(12):3071-9. doi:10.1002/ajmg.a.355899. Golub JS, Brickman AM, Ciarleglio AJ, Schupf N, Luchsinger JA. Association of Subclinical Hearing Loss With Cognitive Performance. JAMA Otolaryngol Head Neck Surg. Jan 1 2020;146(1):57-67. doi:10.1001/jamaoto.2019.337510. Golub JS, Brickman AM, Ciarleglio AJ, Schupf N, Luchsinger JA. Audiometric Age-Related Hearing Loss and Cognition in the Hispanic Community Health Study. J Gerontol A Biol Sci Med Sci. Feb 14 2020;75(3):552-560. doi:10.1093/gerona/glz11911. Zarchi O, Attias J, Raveh E, Basel-Vanagaite L, Saporta L, Gothelf D. A comparative study of hearing loss in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes. J Pediatr. Feb 2011;158(2):301-6. doi:10.1016/j.jpeds.2010.07.05612. Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. [The “Muenster classification”of high frequency hearing loss following cisplatin chemotherapy]. Hno. Apr 2007;55(4):299-306. Die “Münsteraner Klassifikation”: Eine neue Einteilung der Hochtonschwerhörigkeit nach Cisplatingabe.doi:10.1007/s00106-005-1368-113. Mazzoli M, Camp GUY, Newton V, Declau F, Parving A. Recommendations for the Description of Genetic and Audiological Data for Families with Nonsyndromic Hereditary Hearing Impairment. Audiological Medicine. 07/11 2009;1:148-150. doi:10.1080/1651386030171314. Margolis RH, Heller JW. Screening tympanometry: criteria for medical referral. Audiology. 1987;26(4):197-208. doi:10.3109/0020609870908154915. ISO. Acoustics — Statistical distribution of hearing thresholds related to age and gender. 2017. 7029:2017 https://www.iso.org/standard/42916.html16. Van Eynde C, Swillen A, Lambeens E, et al. Prevalence and Nature of Hearing Loss in 22q11.2 Deletion Syndrome. J Speech Lang Hear Res. Jun 1 2016;59(3):583-9. doi:10.1044/2015_jslhr-h-15-009817. Tian C, Johnson KR. TBX1 is required for normal stria vascularis and semicircular canal development. Dev Biol. Jan 1 2020;457(1):91-103. doi:10.1016/j.ydbio.2019.09.01318. Loos E, Verhaert N, Willaert A, et al. Malformations of the middle and inner ear on CT imaging in 22q11 deletion syndrome. Am J Med Genet A. Nov 2016;170(11):2975-2983. doi:10.1002/ajmg.a.3787219. Huang Q, Tang J. Age-related hearing loss or presbycusis. Eur Arch Otorhinolaryngol. Aug 2010;267(8):1179-91. doi:10.1007/s00405-010-1270-720. Boot E, Butcher NJ, Udow S, et al. Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology. Jun 5 2018;90(23):e2059-e2067. doi:10.1212/wnl.000000000000566021. Van L, Heung T, Malecki SL, et al. 22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine. Sep 2020;26:100528. doi:10.1016/j.eclinm.2020.100528